Few reports have investigated biomarkers predicting the efficacy of adjuvant therapy and the risk of postoperative recurrence in patients with completely resected EGFR‐mutated NSCLC, particularly in conjunction with data from interventional studies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.